FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP

- 1											
	OMB APPROVAL										
	OMB Number: 3235-028										
	Estimated average	burden									
	hours per response	: 0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Smith Julie			5	2. Issuer Name and Ticker or Trading Symbol Stoke Therapeutics, Inc. [STOK]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/13/2023							Officer below)	(give title		Other (s below)	pecify	
C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE			4	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person							
(Street) BEDFO	RD M	A	01730											filed by More	•	Ü	
(City)	(S	tate)	(Zip)	F	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							ed to					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da			ate	Execution Date,		Code (Instr. 5)			Benefic Owned	es Form ially (D) o Following (I) (II		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership				
				Code V Amount (A) or P		Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)						
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) if any		Cod	nsaction of		Expiration [Expiration Date (Month/Day/Year) Ar Se Ur		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	у	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Cod	e V	(A)	(D)	Date Exercisable		opiration	Title	Amount or Number of Shares					
Director Stock Option (Right to Buy)	\$12.46	06/13/2023		A		19,441		(1)	06	6/12/2033	Common Stock	19,441	\$0.00	19,441		D	

Explanation of Responses:

1. The option shall fully vest on June 13, 2024 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date.

Remarks:

/s/ Stephen Tulipano, Attorney-06/15/2023 in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.